<DOC>
	<DOCNO>NCT00766064</DOCNO>
	<brief_summary>Chronic posttraumatic stress disorder ( PTSD ) debilitate disorder treatment response pharmacological intervention modest patient . Chronic elevate anxiety associate psychophysiological parameter include increased heart rate alteration skin conductance key symptom chronic PTSD . Antidepressants , include selective serotonin reuptake inhibitor ( SRIs ) norepinephrine-serotonin re-uptake inhibitor consider treatment first choice patient , however substantial portion patient respond sufficiently ( Zhang Davidson 2007 ) . Therefore , need establish novel effective add-on treatment strategy patient . Recently , atypical neuroleptic receive considerable attention since show multiple control naturalistic trial medication effective treatment option patient PTSD ( Davis et al 2006 ) . In chronic PTSD , psychophysiological response baseline response treatment yet inadequately study may provide novel insight antidepressant anxiolytic mechanism medication use treatment PTSD . Therefore , addition evaluate antidepressant anxiolytic effect paliperidone , novel atypical neuroleptic , treatment PTSD , also aim compare neurophysiological response baseline post-treatment effect antidepressant-refractory PTSD patient . Primary Aim 1 : Evaluate anxiolytic antidepressant effect paliperidone patient PTSD . Secondary Aim 2 : Evaluate effect paliperidone fear condition psychophysiological response ( include startle eyeblink , skin conductance , cardiovascular inter-beat interval ) baseline 6 week naturalistic treatment chronic PTSD patient .</brief_summary>
	<brief_title>Effects Paliperidone Posttraumatic Stress Disorder ( PTSD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>willingness participate naturalistic treatment study use paliperidone two fear conditioning test , one baseline one end 6 week treatment study . We include PTSD subject medication ( possible medication include antidepressant , benzodiazepine ) partial treatment response . Paliperidone add exist treatment regime remain unchanged study period . PTSD subject minimum score 50 ClinicianAdministered PTSD Scale ( CAPS ; Blake et al , 1995 ) . comorbid diagnosis bipolar illness , schizophrenia psychotic disorder , acute chronic suicidality , acute chronic unstable medical condition ( include severely impaired hepatic function indicate abnormal PT PTT , abnormal CBC , liver enzymes 50 % upper normal range , well control blood pressure ) current diagnosis substance abuse dependence unsuccessful treatment history paliperidone know hypersensitivity paliperidone inactive ingredient administration investigational drug 90 day entry study intake Class 1A ( e.g. , quinidine , procainamid ) Class III ( e.g. , amiodaronme , sotalol ) antiarrhythmic medication , antipsychotic , antibiotic ( e.g. , gatifloxacin , moxifloxacin ) ( 90 day entry study study ) subject positive screen drug abuse startle skin conductance response , excessively high startle response startle probe ( 100 dB acoustic stimulus ) pretest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>posttraumatic stress disorder</keyword>
</DOC>